Stock Comparison

ADAP vs JNJ

Adaptimmune Therapeutics PLC vs Johnson & Johnson

The Verdict

JNJ takes this one.

ADAP

Adaptimmune Therapeutics PLC

0.5

out of 10

Distressed

Winner

JNJ

Johnson & Johnson

1.0

out of 10

Distressed

Head-to-Head

$17M

Market Cap

N/A

0.0

P/E Ratio

N/A

-260.8%

Profit Margin

N/A

-163.7%

Return on Equity

N/A

0.0

Debt-to-Equity

N/A

Aggressive

Overall Risk

Conservative

0.5

DVR Score

1.0

The Deep Dive

ADAP0.5/10

Adaptimmune's score has plummeted due to a critical and rapid deterioration in its financial and operational status. The share price has collapsed by 90% since the last analysis, now at $0.0022 with an effective $0.00B market cap, signaling imminent failure. Most critically, the company is severely delinquent, having missed Q2, Q3, Q4 2025, and Q1 2026 earnings reports. This strongly indicates the...

Full ADAP Analysis

JNJ1.0/10

Johnson & Johnson (JNJ) remains a fundamentally strong, diversified healthcare conglomerate with an impressive market capitalization. While possessing robust financials, wide economic moats, and consistent performance, its sheer size ($579.46B) fundamentally misaligns with the criteria for 10x growth within a 3-5 year timeframe. A 10x return would necessitate a market cap exceeding $5.7 trillion, ...

Full JNJ Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.